Merit Medical Awarded Interventional Fluid Management Agreement With Premier
June 11 2019 - 9:25AM
Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer
and marketer of proprietary disposable devices used in
interventional, diagnostic and therapeutic procedures, particularly
in cardiology, radiology, oncology, critical care and endoscopy,
announced today that it has been awarded a group purchasing
agreement for interventional fluid management products with
Premier. Effective July 1, 2019, this agreement provides for
Premier members, at their discretion, to take advantage of
negotiated commercial terms for Merit’s interventional fluid
management portfolio of products.
“Since our inception, our interventional fluid
management products have been foundational to Merit's success and a
key driver of our progress,” said Fred P. Lampropoulos, Merit
Chairman and CEO. “For more than three decades, we’ve delivered
quality and innovative interventional fluid management devices,
kits, and packs, and this agreement speaks to the quality,
reliability, and clinical acceptance by clinicians throughout the
United States. The awarding of this contract is a testament to the
consistency and strength of the product portfolio that this company
was built on.”
Within the interventional fluid management
category, Merit offers an integrated suite of products designed to
effectively manage patient fluid levels, imaging media, and waste
in diagnostic and interventional procedures. Merit’s interventional
fluid management portfolio complements Merit’s cardiac and
peripheral intervention products such as the Prelude IDeal™ and
PreludeSYNC™.
Merit’s interventional fluid management products
are designed to meet clinicians’ unique clinical requirements.
Merit offers standard and customized options that can improve
safety, optimize efficiency (by minimizing set-up and take-down
time), and reduce costs within the diagnostic and interventional
environment. For more information on Merit’s line-up of
interventional fluid management solutions, including instructions
for use, visit
www.merit.com/cardiovascular-and-critical-care/interventional-fluid-management.
Premier is a leading healthcare improvement
company, uniting an alliance of approximately 4,000 U.S. hospitals
and 165,000 other providers to transform healthcare. With
integrated data and analytics, collaboratives, supply chain
solutions, and advisory and other services, Premier enables better
care and outcomes at a lower cost.
ABOUT MERITFounded in 1987,
Merit Medical Systems, Inc. is engaged in the development,
manufacture and distribution of proprietary disposable medical
devices used in interventional, diagnostic and therapeutic
procedures, particularly in cardiology, radiology, oncology,
critical care and endoscopy. Merit serves client hospitals
worldwide with a domestic and international sales force and
clinical support team totaling in excess of 300
individuals. Merit employs approximately 6,300 people
worldwide with facilities in South Jordan, Utah; Pearland, Texas;
Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts;
San Jose and Aliso Viejo, California; Maastricht and Venlo, The
Netherlands; Paris, France; Galway, Ireland; Beijing, China;
Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada;
Melbourne, Australia; Tokyo, Japan; Reading, United Kingdom;
Johannesburg, South Africa; and Singapore.
FORWARD-LOOKING
STATEMENTSStatements contained in this release which are
not purely historical, including, without limitation, statements
regarding Merit's forecasted plans and projected results of the
execution of the group purchasing agreement discussed above, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 and are subject to risks
and uncertainties such as those described in Merit's Annual Report
on Form 10-K for the year ended December 31, 2018 and subsequent
filings with the Securities and Exchange Commission. Such
risks and uncertainties include inherent risks and uncertainties
relating to Merit’s internal forecasts and projections; risks
relating to Merit's potential inability to successfully manage
growth through acquisitions generally, including the inability to
effectively integrate acquired operations or products or
commercialize technology acquired through completed, proposed or
future transactions; expenditures relating to research,
development, testing and regulatory approval or clearance of
Merit's products and risks that such products may not be developed
successfully or approved for commercial use; governmental scrutiny
and regulation of the medical device industry, including
governmental inquiries, investigations and proceedings involving
Merit; restrictions on Merit's liquidity or business
operations resulting from its debt agreements; infringement of
Merit's technology or the assertion that Merit's technology
infringes the rights of other parties; product recalls and product
liability claims; changes in customer purchasing patterns or the
mix of products Merit sells; risks and uncertainties associated
with Merit’s information technology systems, including the
potential for breaches of security and evolving regulations
regarding privacy and data protection; the potential of fines,
penalties or other adverse consequences if Merit's employees or
agents violate the U.S. Foreign Corrupt Practices Act or other laws
or regulations; the pending exit of the United Kingdom from the
European Union and uncertainties about when, how or if such exit
will occur; laws and regulations targeting fraud and abuse in the
healthcare industry; potential for significant adverse changes in
governing regulations, including reforms to the procedures for
approval or clearance of Merit's products by the U.S. Food &
Drug Administration or comparable regulatory authorities in other
jurisdictions; changes in tax laws and regulations in the United
States or other countries; increases in the prices of commodity
components; negative changes in economic and industry conditions in
the United States or other countries; termination or interruption
of relationships with Merit's suppliers, or failure of such
suppliers to perform; fluctuations in exchange rates; uncertainties
relating to the LIBOR calculation method and the potential phasing
out of LIBOR; concentration of a substantial portion of Merit's
revenues among a few products and procedures; development of new
products and technology that could render Merit's existing products
obsolete; market acceptance of new products; volatility in the
market price of Merit's common stock; modification or limitation of
governmental or private insurance reimbursement policies; changes
in healthcare policies or markets related to healthcare reform
initiatives; failure to comply with applicable environmental laws;
changes in key personnel; work stoppage or transportation risks;
introduction of products in a timely fashion; price and product
competition; availability of labor and materials; fluctuations in
and obsolescence of inventory; and other factors referred to in
Merit's Annual Report on Form 10-K for the year ended December 31,
2018 and other materials filed with the Securities and Exchange
Commission. All subsequent forward-looking statements attributable
to Merit or persons acting on its behalf are expressly qualified in
their entirety by these cautionary statements. Actual results will
likely differ, and may differ materially, from anticipated results.
Financial estimates are subject to change and are not intended to
be relied upon as predictions of future operating results, and
Merit assumes no obligation to update or disclose revisions to
those estimates.
Contact: Anne-Marie Wright, Vice
President, Corporate CommunicationsPhone:
(801) 208-4167 e-mail:
awright@merit.com Fax: (801) 253-1688
Merit Medical Systems (NASDAQ:MMSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merit Medical Systems (NASDAQ:MMSI)
Historical Stock Chart
From Apr 2023 to Apr 2024